Evidence map›Paper›PMID 40236761›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2025

Real-World Effectiveness of Single-Inhaler Triple Treatment Through Assorted Respiratory Outcomes When Switched From Multiple-Inhaler Triple Therapies (RESTART): A Prospective Cohort Study of Korean Patients With COPD.

Hana Lim, Dong Han Kim, Song Hee Hong, Juyoung Shin, Hyesung Lee, Kyeongcheol Shin, Seung Won Ra, Seung Jun Lee

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hana Lim *Department of Bio Health Regulatory Science, Sungkyunkwan University, Suwon, Korea.ORCID 0009-0009-5894-4147
Dong Han Kim *Department of Social Pharmacy, Seoul National University, Seoul, Korea.ORCID 0000-0002-4507-2038
Song Hee HongDepartment of Social Pharmacy, Seoul National University, Seoul, Korea.ORCID 0000-0002-5188-9837
Juyoung ShinDepartment of Bio Health Regulatory Science, Sungkyunkwan University, Suwon, Korea.ORCID 0000-0003-1010-7525
Hyesung LeeDepartment of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Korea.
Kyeongcheol ShinDivision of Pulmonology and Allergy, Regional Center for Respiratory Disease, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea.ORCID 0000-0003-1972-1847
Seung Won RaDivision of Pulmonology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.ORCID 0000-0002-2458-8414
Seung Jun LeeDivision of Pulmonology, Department of Internal Medicine, Gyeongsang National University, Jinju, Korea.ORCID 0000-0002-1849-5086

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition characterized by persistent airflow limitation, leading to significant morbidity and mortality. Despite the effectiveness of multiple inhaler triple therapy (MITT), its complexity often results in poor adherence and suboptimal outcomes. Transitioning to single inhaler triple therapy (SITT) may enhance adherence, leading to improved clinical outcomes and quality of life of patients. The Real-World Effectiveness of Single Inhaler Triple Treatment through Assorted Respiratory Outcomes when Switched from Multiple Inhaler Triple Therapies (RESTART) study aimed to evaluate the clinical benefits of switching from MITT to SITT using fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in a real-world Korean setting. Patients and Methods: This prospective, multicenter, observational study enrolled 107 patients, aged 40 and older, with diagnosed COPD, all previously on MITT. The patients were transitioned to once-daily FF/UMEC/VI administered via the ELLIPTA inhaler. The primary outcome was a change in the COPD Assessment Test (CAT) score after 24 weeks. The secondary outcomes included changes in lung function, exacerbation rates, Modified Medical Research Council Dyspnea Scale scores, and Treatment Satisfaction-Visual Analysis Scale (TS-VAS) scores. Results: A total of 91 patients completed the 24-week observation. CAT scores significantly improved (mean change = 1.40 points, Conclusion: The transition from MITT to SITT significantly improved COPD symptom management, pulmonary function, exacerbation rate, and treatment satisfaction in Korean cohort. Using a single inhaler to simplify therapy might increase patient compliance and improve clinical outcomes of COPD management.

Indexed as

Adrenergic beta-2 Receptor AgonistsBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug SubstitutionLungMuscarinic AntagonistsNebulizers and VaporizersPulmonary Disease, Chronic ObstructiveQuinuclidinesAdministration, InhalationAdultAgedAndrostadienesDrug CombinationsFemaleAdrenergic beta-2 Receptor AgonistsAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug Combinationsfluticasone furoateGSK573719Muscarinic AntagonistsQuinuclidinesvilanteroladherencechronic obstructive pulmonary diseasechronic obstructive pulmonary disease assessment test scorereal-world evidencesingle-inhaler triple treatment

Identifiers

PMID40236761
PMCPMC11998983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.